Cleveland Clinic - Taussig Cancer Center

Taussig Cancer Institute

Cleveland, OH

Sorting 11 by

Not yet accepting

QUINTESSENTIAL-2

Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

SUCCESSOR-1

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Randomization
  • Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

EXCALIBER - Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3

Accepting patients

MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
  • Bispecific Antibody
  • CD3
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

MagnetisMM-7

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
  • Bispecific Antibody
  • GPRC5D
  • Phase 3

Accepting patients

P-BCMA-ALLO1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Has results

Accepting patients

APG-2575

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
1 hidden based on your filters. Show All